Renal tumor biomarkers (Review)
Experimental and Therapeutic Medicine, 2021 One of the most common types of cancer worldwide (9th most commonly diagnosed) is renal cell carcinoma (RCC). It is more common in developed countries and it usually develops in individuals between 60 and 70 years of age. The earlier the disease is identified, the lower the morbidity.
Ovidiu Gabriel Bratu +11 more
openaire +4 more sources
The importance of circulating tumor products as „liquid biopsies” in colorectal cancer [PDF]
, 2018 Liquid biopsies represent an array of plasma analysis tests that are studied to evaluate and identify circulating tumor products, especially circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).
Calborean, Veronica +6 more
core +4 more sources
Cancer Control, 2009 Background Morphologic and histopathologic markers have been the backbone for the classification and prognostic assessment of melanoma. Availability of an increasing number of molecular markers, however, provides the potential for refining diagnostic and prognostic categories in this disease.
Jüurgen C Becker +2 more
openaire +3 more sources
Ubiquinol Reduces Muscle Wasting but Not Fatigue in Tumor-Bearing Mice [PDF]
, 2014 Purpose: Fatigue is the most common and distressing symptom reported by cancer patients during and after treatment. Tumor growth increases oxidative stress and cytokine production, which causes skeletal muscle wasting and cardiac dysfunction. The purpose
Clark, Yvonne +3 more
core +2 more sources
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib [PDF]
, 2016 ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC.
Abbadessa, Giovanni +19 more
core +4 more sources
A caspase-3 'death-switch' in colorectal cancer cells for induced and synchronous tumor apoptosis in vitro and in vivo facilitates the development of minimally invasive cell death biomarkers [PDF]
, 2013 Novel anticancer drugs targeting key apoptosis regulators have been developed and are undergoing clinical trials. Pharmacodynamic biomarkers to define the optimum dose of drug that provokes tumor apoptosis are in demand; acquisition of longitudinal tumor
Brown, G. +14 more
core +2 more sources
CD44 as a tumor biomarker and therapeutic target [PDF]
Experimental Hematology & Oncology, 2020 AbstractCD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple physiological processes, and aberrant expression and dysregulation of CD44 contribute to tumor initiation and progression. CD44 represents a common biomarker of cancer stem
Kongming Wu +5 more
openaire +3 more sources
Molecular and Circulating Biomarkers of Brain Tumors [PDF]
International Journal of Molecular Sciences, 2021 Brain tumors are the most common malignant primary intracranial tumors of the central nervous system. They are often recognized too late for successful therapy. Minimally invasive methods are needed to establish a diagnosis or monitor the response to treatment of CNS tumors. Brain tumors release molecular information into the circulation.
Wojciech Jelski, Barbara Mroczko
openaire +2 more sources
Focused ultrasound-enabled brain tumor liquid biopsy [PDF]
, 2018 Although blood-based liquid biopsies have emerged as a promising non-invasive method to detect biomarkers in various cancers, limited progress has been made for brain tumors.
Chen, Hong +10 more
core +3 more sources
A Pilot Study Comparing HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas by Whole Exome Sequencing. [PDF]
, 2012 Background. Next-generation sequencing of cancers has identified important therapeutic targets and biomarkers. The goal of this pilot study was to compare the genetic changes in a human papillomavirus- (HPV-)positive and an HPV-negative head and neck ...
Barrett, John W +19 more
core +3 more sources